Research Progress on Postoperative Minimal/Molecular Residual Disease Detection in Lung Cancer.

ABSTRACT: Lung cancer is the leading cause of cancer-related deaths worldwide. Approximately 10%-50% of patients experience relapse after radical surgery, which may be attributed to the persistence of minimal/molecular residual disease (MRD). Circulating tumor DNA (ctDNA), a common liquid biopsy approach, has been demonstrated to have significant clinical merit. In this study, we review the evidence supporting the use of ctDNA for MRD detection and discuss the potential clinical applications of postoperative MRD detection, including monitoring recurrence, guiding adjuvant treatment, and driving clinical trials in lung cancer. We will also discuss the problems that prevent the routine application of ctDNA MRD detection. Multi-analyte methods and identification of specific genetic and molecular altera

SUBMITTER: Wu M 

PROVIDER: S-EPMC9215711 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature